Sarepta Therapeutics and Summit Enter Into Exclusive License and Collaboration Agreement for European Rights to Summit’s Utrophin Modulator Pipeline for the Treatment of Duchenne Muscular Dystrophy

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/20/2026

1. TGT
2. EL
3. MRK
4. BILL
5. MRNA
6. COTY
7. RARE
8. LOW
9. DE
10. ADI

Go back to Sarepta Therapeutics and Summit Enter Into Exclusive License and Collaboration Agreement for European Rights to Summit’s Utrophin Modulator Pipeline for the Treatment of Duchenne Muscular Dystrophy
Stratcomm Media, Ltd. (NASDAQ: SMMT) Delayed: 13.11 --0 (-0%)
Previous Close $13.11    52 Week High $19.75 
Open $13.11    52 Week Low $4.26 
Day High $13.11    P/E N/A 
Day Low $13.11    EPS $0.00 
Volume 21,772       

SAREPTA THERAP (NASDAQ: SRPT) Delayed: 19.73 --0 (-0%)
Previous Close $19.73    52 Week High $63.73 
Open $19.73    52 Week Low $8.00 
Day High $19.73    P/E N/A 
Day Low $19.73    EPS $-5.69 
Volume 9,419       

AyreTrade, Inc. (AMEX: SUMM) Delayed: 0.06 --0 (-0%)
Previous Close $0.06    52 Week High $0.24 
Open $40.78    52 Week Low $0.02 
Day High $0.06    P/E N/A 
Day Low $0.06    EPS $0.00 
Volume 7,226,927